Jazz Veno-Occlusive Disease Drug Defitelio OK'd
This article was originally published in Scrip
Executive Summary
Jazz Pharmaceuticals PLC won the FDA's approval on March 30 for the company's anticoagulant Defitelio (defibrotide) as a treatment for adults and children with hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT) – the first medicine available in the US for that indication.
You may also be interested in...
Deal Watch: Merck, Incyte Double Down On Keytruda/Epacadostat Collaboration
Expansion of 2015 development partnership adds lung and bladder cancer as well as renal and head-and-neck carcinoma to trials of the two immuno-oncology drugs. Jazz licenses Japanese rights to two of its commercial products to Nippon Shinyaku.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.